The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
|Articles|March 21, 2014
Medis and Onkodatamed Link Up for Oncology Trials
Author(s)Philip Ward
Medis Research Group has been joined by ONKODATAMED GmbH in a bid to consolidate the group's position as an oncology trial specialist...
Advertisement
Medis Research Group, a strategic alliance of Berlin-based CROs, has been joined by another CRO from the Berlin area, ONKODATAMED GmbH, in a bid to consolidate the group’s position as an oncology trial specialist covering Germany, Austria and Switzerland.
Medis was founded in November 2013, and its two founding members were Allied Clinical Management and ICRC-Weyer. The group was formed in a move to better meet requirements of clinical trial sponsors for "one-stop shop solutions."
Onkodatamed is a specialist provider of remote data capture solutions within a network of dermatologic, urologic and gynecologic oncologists. Through this network, Medis now has access to one of the largest epidemiological and clinical oncology databases in Europe containing information on thousands of patients currently in treatment – a valuable source for retrospective data analysis.
“The group’s clinical research services complement the portfolio of Onkodatamed enabling us to jointly provide a wide range of services for the conduct of entire trial projects and retrospective data analysis. On the other hand, we can contribute to the group with our proven remote data capture software ODM QuaSi as well as our large database of urologic and gynecologic oncology patients,” said Dr. Lutz Reimer, Managing Director of Onkodatamed.
Advertisement
Related to this article
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, argues that CROs must act as orchestrators rather than aggregators—and that the real test of any AI ecosystem is whether it reduces sponsor coordination burden or just hands it back to them.
Syneos Health and Optum outline a joint model for trial planning, recruitment and site access, with no financial terms or timelines disclosed.
AstraZeneca and Oracle Outline AI Collaboration for Clinical Trial Recruitment and Safety Monitoring
What sponsors and sites should know about the AstraZeneca-Oracle AI collaboration on trial recruitment, safety monitoring and data governance.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
2
Where AI Governance in Clinical Development Falls Short
3
Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology
4
Syneos Health, Optum Partner on Adaptive Clinical Development Model
5